Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
NCT02514824Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sapanisertib in Merkel cell carcinoma (MCC), sponsored by Dana-Farber Cancer Institute. Started Oct 2015; status: completed.
02
Drugs
sapanisertib
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT02514824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514824.